Activation of Cyclin-Dependent Kinases by Fructose-2,6-Bisphosphate

2,6-二磷酸果糖激活细胞周期蛋白依赖性激酶

• 批准号: 8250362
• 负责人: Jason A. Chesney
• 金额: $ 31.07万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2016-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8250362
• 关键词: 6-Phosphofructo-2-kinase; 6-Phosphofructokinase; Affect; Amino Acids; Apoptosis; Binding; CDC2 Protein Kinase; CDK2 gene; CDK4 gene; Cancer cell line; Cell Cycle; Cell Cycle Progression; Cell Cycle Regulation; Cell Nucleus; Cell division; Cells; Cyclin-Dependent Kinases; Cyclins; Cytoplasm; Cytostatics; DNA biosynthesis; Data; Enzymes; Epithelial; Epithelial Cells; Eukaryotic Cell; Family; Family member; Fructose; G1/S Transition; Genes; Genetic Transcription; Genomics; Glycolysis; Growth; Hela Cells; Hematopoietic; Human; Human Development; Hypoxia; In Vitro; Liver; Malignant Neoplasms; Mitosis; Molecular Target; Mus; Mutation; Normal Cell; Normal tissue morphology; Nuclear; Oncogenes; Pathway interactions; Phosphoric Monoester Hydrolases; Phosphotransferases; Protein p53; Recombinants; Regulation; Relative (related person); Research; Role; Screening procedure; Signal Pathway; Site; Small Interfering RNA; Testing; Tissues; Transfection; Transformed Cell Line; Transgenic Organisms; base; cancer cell; chemotherapeutic agent; clinically significant; fructose-6-phosphate; glucose metabolism; glucose uptake; in vitro activity; interest; mutant; neoplastic; novel; public health relevance; receptor; small molecule; tumor; tumor growth; tumor progression; virtual

DESCRIPTION (provided by applicant): The 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFKFB) phosphorylate fructose-6-phosphate (F6P) to fructose-2,6-bisphosphate (F2,6BP), which is an allosteric activator of 6-phosphofructo-1-kinase, a rate-limiting enzyme in the glycolytic pathway. Although there are four PFKFB enzymes, PFKFB3 and PFKFB4 are of particular interest since these enzymes have been found to be activated in human cancers, to be increased by hypoxic exposure via HIF-1?, and, in the case of PFKFB3, to be required for the growth of Ras-transformed tumors. In order to better understand the relative contributions of PFKFB2-4 to glycolysis, we examined the subcellular localization of these enzymes and were surprised to find that whereas PFKFB2 and PFKFB4 localized to the cytoplasm (the site of glycolysis), PFKFB3 localized to the nucleus. We then over-expressed PFKFB3 in HeLa cells and observed no change in glucose uptake but rather an increase in proliferation. Eukaryotic cell division is controlled by cyclin dependent kinases (CDKs) that bind to regulatory cyclins and phosphorylate hundreds of substrates that control DNA replication, transcription and mitosis. We found that over-expression of PFKFB3 stimulated CDK1 activity in HeLa cells and that purified F2,6BP stimulated recombinant monomeric CDK1 in vitro. We then confirmed the requirement of CDK1 for the pro-proliferative effects of PFKFB3 by demonstrating that CDK1 siRNA but not CDK2, CDK4 or CDK6 siRNA reversed the increased proliferation caused by over-expression of PFKFB3. Importantly, transfection of HeLa cells with PFKFB3-specific siRNA decreased endogenous PFKFB3 which in turn reduced CDK1 activity, increased p27 expression, suppressed G1/S transition, induced apoptosis but had no impact on glucose uptake. These data support a distinct role for PFKFB3 in the regulation of cell cycle progression and apoptosis, and not glucose metabolism. We propose to test the hypothesis that nuclear F2,6BP generated by PFKFB3 activates CDKs and promotes cell cycle progression. We anticipate that nuclear F2,6BP may serve unique roles in regulating CDK1, and other CDKs, and that inhibition of PFKFB3 will suppress CDK activities without significantly affecting glucose metabolism in transformed but not in normal cells. PUBLIC HEALTH RELEVANCE: The research proposed in this application may enable the identification of a novel molecular target - the CDK1 F2,6BP-binding domain - that is required for the regulation of the cell cycle and cancer progression. This binding pocket then can be used for receptor-based virtual screening to identify novel anti-neoplastic agents.

描述（由申请人提供）：6-磷酸果糖-2-激酶/果糖-2，6-二磷酸酶（PFKFB）将果糖-6-磷酸（F6 P）磷酸化为果糖-2，6-二磷酸（F2，6 BP），后者是糖酵解途径中的限速酶6-磷酸果糖-1-激酶的变构激活剂。虽然有四种PFKFB酶，但PFKFB 3和PFKFB 4特别令人感兴趣，因为已经发现这些酶在人类癌症中被激活，通过HIF-1？并且在PFKFB 3的情况下，是Ras转化肿瘤生长所需的。为了更好地理解PFKFB 2 -4对糖酵解的相对贡献，我们检查了这些酶的亚细胞定位，并惊讶地发现PFKFB 2和PFKFB 4定位于细胞质（糖酵解的位点），而PFKFB 3定位于细胞核。然后，我们在HeLa细胞中过表达PFKFB 3，并观察到葡萄糖摄取没有变化，而是增殖增加。真核细胞分裂受细胞周期蛋白依赖性激酶（CDK）控制，CDK与调节性细胞周期蛋白结合并磷酸化数百种控制DNA复制、转录和有丝分裂的底物。我们发现，PFKFB 3的过表达刺激HeLa细胞中的CDK 1活性，纯化的F2，6 BP刺激重组单体CDK 1在体外。然后，我们通过证明CDK 1 siRNA而不是CDK 2、CDK 4或CDK 6 siRNA逆转了由PFKFB 3过表达引起的增殖增加，证实了PFKFB 3的促增殖作用需要CDK 1。重要的是，用PFKFB 3特异性siRNA转染HeLa细胞降低了内源性PFKFB 3，进而降低了CDK 1活性，增加了p27表达，抑制了G1/S转换，诱导了细胞凋亡，但对葡萄糖摄取没有影响。这些数据支持PFKFB 3在调节细胞周期进展和细胞凋亡方面发挥独特作用，而不是葡萄糖代谢。我们建议验证PFKFB 3产生的核F2，6 BP激活CDK并促进细胞周期进程的假设。我们预计，核F2，6 BP可能在调节CDK 1和其他CDK中发挥独特的作用，并且PFKFB 3的抑制将抑制CDK活性，而不会显著影响转化细胞而不是正常细胞的葡萄糖代谢。 公共卫生关系：本申请中提出的研究可能能够鉴定一种新的分子靶点-CDK 1 F2，6 BP结合结构域-这是调节细胞周期和癌症进展所必需的。然后，该结合口袋可用于基于受体的虚拟筛选以鉴定新型抗肿瘤剂。